The Next Wave of Immune Cell Therapy - Takeaways - MDSpire

The Next Wave of Immune Cell Therapy

From CAR T to eTCR: New immune cell therapies push beyond blood cancers

  • April 1, 2026

  • 18 min

Share

  • 1

    Kevin Tronkowski participated in a phase 1 clinical trial for engineered T-cell receptor (eTCR) T cells targeting colorectal cancer.

  • 2

    eTCR T cells are designed to target tumors with specific genetic mutations and require patients to meet certain eligibility criteria.

  • 3

    The development of eTCR T cells follows the success of CAR T cells, which are now standard treatments for certain blood cancers.

  • 4

    Both eTCR and CAR T cell therapies are engineered but differ in their mechanisms for targeting cancer cells.

  • 5

    Dana-Farber researchers are exploring eTCR T cells for solid tumors, expanding the potential of immune cell therapies beyond blood cancers.

Original Source(s)

The Next Wave of Immune Cell Therapy

  • April 1, 2026

Related Content

STOPGAP II — a national randomized clinical trial for patients with stage 4 gastric cancer

What starts at UCI Health can help shape the national conversation.

  • June 30, 2026

  • 1 min
Two Dana-Farber Hematologists Receive Top Honors From the American Society of Hematology

The American Society of Hematology is recognizing 11 distinguished hematologists with its most prestigious awards and named lectures, honoring transformative contributions that have advanced research, patient care, and education in blood disorders. Two of this year’s honorees are from Dana-Farber Cancer Institute: Benjamin L. Ebert, MD, PhD, and Scott A. Armstrong, MD, PhD.

  • by

  • June 23, 2026

  • 4 min
Promising phase 1 data presented by UCI Health radiologist at ASCO 2026

Nadine Abi-Jaoudeh, MD shared promising Phase 1 data at ASCO 2026 regarding a novel interventional approach for locally advanced pancreatic cancer.

  • June 22, 2026

  • 1 min